Literature DB >> 7514684

Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

T Muster1, R Guinea, A Trkola, M Purtscher, A Klima, F Steindl, P Palese, H Katinger.   

Abstract

Previously we identified the highly conserved amino acids Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) on the ecto-domain of gp41 as the epitope of a neutralizing monoclonal antibody (2F5) directed against human immunodeficiency virus type 1. In the present study, the sequence defining the epitope was introduced into the loop of antigenic site B of the influenza virus hemagglutinin. The resulting chimeric virus was able to elicit ELDKWA-specific immunoglobulins G and A in antisera of mice. Moreover, the distantly related human immunodeficiency virus type 1 isolates MN, RF, and IIIB were neutralized by these antisera. These data suggest that this conserved B-cell epitope is a promising candidate for inclusion in a vaccine against AIDS. The results also show that influenza virus can be used to effectively present the antigenic structure of this B-cell epitope.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514684      PMCID: PMC236911     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  In vitro generation of an HTLV-III variant by neutralizing antibody.

Authors:  M Robert-Guroff; M S Reitz; W G Robey; R C Gallo
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

2.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

Authors:  M S Reitz; C Wilson; C Naugle; R C Gallo; M Robert-Guroff
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

3.  An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.

Authors:  D J Evans; J McKeating; J M Meredith; K L Burke; K Katrak; A John; M Ferguson; P D Minor; R A Weiss; J W Almond
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

4.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

5.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

6.  Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells.

Authors:  J L Schulman; P Palese
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

7.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Authors:  T J Matthews; A J Langlois; W G Robey; N T Chang; R C Gallo; P J Fischinger; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Variable and conserved neutralization antigens of human immunodeficiency virus.

Authors:  R A Weiss; P R Clapham; J N Weber; A G Dalgleish; L A Lasky; P W Berman
Journal:  Nature       Date:  1986 Dec 11-17       Impact factor: 49.962

9.  Type-restricted neutralization of molecular clones of human immunodeficiency virus.

Authors:  D J Looney; A G Fisher; S D Putney; J R Rusche; R R Redfield; D S Burke; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

10.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

View more
  131 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 5.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

6.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Protein grafting of an HIV-1-inhibiting epitope.

Authors:  Samuel K Sia; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

Review 8.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

9.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.